Review Article | Published:

Clinical pancreatic islet transplantation

Nature Reviews Endocrinology volume 13, pages 268277 (2017) | Download Citation

Abstract

Clinical pancreatic islet transplantation can be considered one of the safest and least invasive transplant procedures. Remarkable progress has occurred in both the technical aspects of islet cell processing and the outcomes of clinical islet transplantation. With >1,500 patients treated since 2000, this therapeutic strategy has moved from a curiosity to a realistic treatment option for selected patients with type 1 diabetes mellitus (that is, those with hypoglycaemia unawareness, severe hypoglycaemic episodes and glycaemic lability). This Review outlines the techniques required for human islet isolation, in vitro culture before the transplant and clinical islet transplantation, and discusses indications, optimization of recipient immunosuppression and management of adjunctive immunomodulatory and anti-inflammatory strategies. The potential risks, long-term outcomes and advances in treatment after the transplant are also discussed to further move this treatment towards becoming a more widely available option for patients with type 1 diabetes mellitus and eventually a potential cure.

Key points

  • Pancreatic islet transplantation is an effective β-cell replacement therapy that has the capacity to normalize glycaemic control in patients with type 1 diabetes mellitus

  • To date, over 1,500 patients have undergone islet transplantation in approximately 40 international centres

  • The long-term clinical outcomes of islet transplantation alone in selected centres are now similar to the results of whole-pancreas transplantation alone, with 50–70% of patients achieving insulin independence at 5 years

  • An NIH funded phase III multicentre trial in North America has confirmed that islet transplantation is a safe and effective method for treatment of patients with type 1 diabetes mellitus complicated by hypoglycaemia unawareness and serve hypoglycaemic events

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Collaborative Islet Transplant Registry. Eighth Annual Report. CITR (2014).

  2. 2.

    State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr. Diab. Rep. 11, 345–354 (2011).

  3. 3.

    et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343, 230–238 (2000).

  4. 4.

    et al. International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. 355, 1318–1330 (2006).

  5. 5.

    & Clinical islet transplantation: advances and immunological challenges. Nat. Rev. Immunol. 4, 259–268 (2004).

  6. 6.

    et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 293, 830–835 (2005).

  7. 7.

    Islet transplantation: a brave new world. Diabetes 52, 1595–1603 (2003).

  8. 8.

    et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am. J. Transplant. 12, 1576–1583 (2012).

  9. 9.

    et al. Long-term insulin-independence after allogeneic islet transplantation for type 1 diabetes: over the 10-year mark. Am. J. Transplant. 9, 419–423 (2009).

  10. 10.

    et al. Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. Diabetes Care 39, 1230–1240 (2016).

  11. 11.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  12. 12.

    , & Islet transplant: an option for childhood diabetes? Arch. Dis. Child. 88, 591–594 (2003).

  13. 13.

    et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am. J. Transplant. 4, 87–93 (2004).

  14. 14.

    & Skin cancer in transplant recipients, out of the woods. Scientific retreat of the ITSCC and SCOPE. Am. J. Transplant. 11, 1584–1591 (2011).

  15. 15.

    et al. Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair. Exp. Dermatol. 21, 2–6 (2012).

  16. 16.

    et al. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349, 931–940 (2003).

  17. 17.

    , , & New-generation diabetes management: glucose sensor-augmented insulin pump therapy. Expert Rev. Med. Devices 8, 449–458 (2011).

  18. 18.

    , , & Are stem cells a cure for diabetes? Clin. Sci. 118, 87–97 (2010).

  19. 19.

    , , , & Differentiation of stem cells into insulin-producing cells: current status and challenges. Arch. Immunol. Ther. Exp. (Warsz.) 61, 149–158 (2013).

  20. 20.

    , & Current indications for pancreas or islet transplant. Diabetes Obes. Metab. 8, 1–7 (2006).

  21. 21.

    , , & New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1, 1253–1257 (1971).

  22. 22.

    et al. BK virus nephropathy in simultaneous pancreas kidney transplant: a potentially preventable cause of kidney allograft loss. Clin. Transplant. 26, E87–E93 (2012).

  23. 23.

    et al. Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrol. Dial. Transplant. 28, 2908–2918 (2013).

  24. 24.

    et al. High risk of sensitization after failed islet transplantation. Am. J. Transplant. 7, 2311–2317 (2007).

  25. 25.

    et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am. J. Transplant. 7, 1242–1248 (2007).

  26. 26.

    & Surgical aspects of human islet isolation. Islets 2, 265–273 (2010).

  27. 27.

    et al. Toward maximizing the success rates of human islet isolation: influence of donor and isolation factors. Cell Transplant. 16, 595–607 (2007).

  28. 28.

    & The new deceased donor pancreas allocation schema: do the recommendations go far enough? Transplantation 83, 1151–1152 (2007).

  29. 29.

    et al. The impact of donor obesity on outcomes after cadaver pancreas transplants. Am. J. Transplant. 4, 605–610 (2004).

  30. 30.

    , , , & Body mass index of pancreatic donors: a decisive factor for human islet isolation. Exp. Clin. Endocrinol. Diabetes 103 (Suppl. 2), 23–26 (1995).

  31. 31.

    et al. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation 61, 1047–1053 (1996).

  32. 32.

    , , , & Multicenter analysis of novel and established variables associated with successful human islet isolation outcomes. Am. J. Transplant. 10, 646–656 (2010).

  33. 33.

    et al. Analysis of donor- and isolation-related variables from non-heart-beating donors (NHBDs) using the Kyoto islet isolation method. Cell Transplant. 17, 649–656 (2008).

  34. 34.

    , & Donor and isolation variables predicting human islet isolation success. Transplantation 85, 950–955 (2008).

  35. 35.

    et al. Islet isolation for allotransplantation: variables associated with successful islet yield and graft function. Diabetologia 48, 906–912 (2005).

  36. 36.

    , , , & The use of multiparametric monitoring during islet cell isolation and culture: a potential tool for in-process corrections of critical physiological factors. Cell Transplant. 13, 497–502 (2004).

  37. 37.

    et al. Human islet distribution program for basic research at a single center. Transplant. Proc. 43, 3195–3197 (2011).

  38. 38.

    et al. Comparison of human islet isolation outcomes using a new mammalian tissue-free enzyme versus collagenase NB-1. Transplantation 90, 255–259 (2010).

  39. 39.

    et al. The standardization of pancreatic donors for islet isolations. Transplantation 80, 801–806 (2005).

  40. 40.

    & Unraveling the secrets of single donor success in islet transplantation. Am. J. Transplant. 4, 295–298 (2004).

  41. 41.

    et al. Altered islet composition and disproportionate loss of large islets in patients with type 2 diabetes. PLoS ONE 6, e27445 (2011).

  42. 42.

    et al. β-Cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am. J. Pathol. 178, 2632–2640 (2011).

  43. 43.

    Survival of an islet β-cell in type-2 diabetes: curbing the effects of amyloid cytotoxicity. Islets 3, 38–39 (2011).

  44. 44.

    et al. Type 2 diabetes mellitus phenotype and graft survival after islet transplantation. Transplantation 88, 57–61 (2009).

  45. 45.

    et al. Pancreas procurement from multiorgan donors for islet trasplantation. Diabetes Nutr. Metab. 5, 39–41 (1992).

  46. 46.

    et al. Procurement of the human pancreas for pancreatic islet transplantation. Transplantation 78, 481–483 (2004).

  47. 47.

    et al. Portal vein thrombosis is a potentially preventable complication in clinical islet transplantation. Am. J. Transplant. 11, 2700–2707 (2011).

  48. 48.

    Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome. Rev. Diabet. Stud. 9, 385–406 (2012).

  49. 49.

    , & Automated islet isolation from human pancreas. Diabetes 38 (Suppl. 1), 140–142 (1989).

  50. 50.

    et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes 39, 515–518 (1990).

  51. 51.

    & 25 years of the Ricordi automated method for islet isolation. CellR4 1, e128 (2013).

  52. 52.

    et al. Purified human pancreatic islets, viability estimation of islet using fluorescent dyes (FDA/PI) — standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 3, e1378 (2015).

  53. 53.

    et al. Purified human pancreatic islets, certificate of analysis (product code PHPI-A-01) — standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 3, e1448 (2015).

  54. 54.

    et al. Purified human pancreatic islets, interim certificate of analysis (product code PHPI-A-01) — standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 3, e1446 (2015).

  55. 55.

    et al. Purified human pancreatic islets, CIT transplant media — standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 3, e1523 (2015).

  56. 56.

    et al. Purified human pancreatic islets, qualitative and quantitative assessment of islets using dithizone (DTZ) — standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 3, e1369 (2015).

  57. 57.

    et al. Purified human pancreatic islets, CIT enzyme solution roche enzymes — standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 3, e1360 (2015).

  58. 58.

    et al. Purified human pancreatic islets, CIT enzyme solution vitacyte enzymes and vitacyte/serva enzymes combination — standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 3, e1350 (2015).

  59. 59.

    et al. Purified human pancreatic islets, CIT enzyme solution: serva enzymes proportional units collagenase & neutral protease — standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 3, e1342 (2015).

  60. 60.

    et al. Purified human pancreatic islets, CIT culture media — a standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 2, e981 (2014).

  61. 61.

    et al. Purified human pancreatic islets, supplementary purification, discontinuous polysucrose procedure and record — a standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 2, e997 (2014).

  62. 62.

    et al. Purified human pancreatic islets, supplementary purification, biocoll procedure and record — a standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 2, e995 (2014).

  63. 63.

    et al. Purified human pancreatic islets, CIT purification density gradients — a standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 2, e999 (2014).

  64. 64.

    et al. Purified human pancreatic islets, CIT purification solution — a standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 2, e993 (2014).

  65. 65.

    et al. Functional assessment of purified human pancreatic islets: glucose stimulated insulin release by ELISA — a standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 2, e900 (2014).

  66. 66.

    et al. Purified human pancreatic islets, specifications (product codes PHPI-A-01, PHPI-L-01, PHPI-E-01) — standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 3, e1437 (2015).

  67. 67.

    et al. Purified human pancreatic islets, (PHPI) master production batch record — a standard operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 2, e891 (2014).

  68. 68.

    et al. NIH-sponsored clinical islet transplantation consortium phase 3 trial: manufacture of a complex cellular product at eight processing facilities. Diabetes (2016).

  69. 69.

    et al. Human pancreatic islet beta-cell destruction by cytokines is independent of nitric oxide production. J. Clin. Endocrinol. Metab. 79, 1058–1062 (1994).

  70. 70.

    et al. Improved in vivo pancreatic islet function after prolonged in vitro islet culture. Transplantation 72, 1730–1736 (2001).

  71. 71.

    , , & Methods of human islet culture for transplantation. Cell Transplant. 13, 605–617 (2004).

  72. 72.

    Islet culture and counter-culture. Commentary on: Effect of short-term culture on functional & stress-related parameters in isolated human islets by Ihm et al. Transpl. Int. 22, 531–533 (2009).

  73. 73.

    , & Pancreatic islet culture and preservation strategies: advances, challenges, and future outlook. Cell Transplant. 19, 1523–1535 (2010).

  74. 74.

    , & Cytotoxic effects of cytokines on islet β-cells: evidence for involvement of eicosanoids. Endocrinology 126, 67–71 (1990).

  75. 75.

    et al. Shipment of human islets for transplantation. Am. J. Transplant. 7, 1010–1020 (2007).

  76. 76.

    et al. Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center. Transplantation 77, 462–466 (2004).

  77. 77.

    et al. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation 74, 1761–1766 (2002).

  78. 78.

    et al. Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US. Radiology 234, 617–624 (2005).

  79. 79.

    , , , & Percutaneous transhepatic catheterization of the portal vein: a combined CT- and fluoroscopy-guided technique. Cardiovasc. Intervent. Radiol. 22, 342–344 (1999).

  80. 80.

    et al. Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am. J. Transplant. 5, 2992–2998 (2005).

  81. 81.

    et al. Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation. Transplantation 78, 172–173 (2004).

  82. 82.

    , , & Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant. 13, 55–59 (2004).

  83. 83.

    , & A comparison of islet autotransplantation with allotransplantation and factors elevating acute portal pressure in clinical islet transplantation. J. Hepatobiliary Pancreat. Sci. 19, 281–288 (2012).

  84. 84.

    et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 54, 1755–1762 (2005).

  85. 85.

    et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation 89, 465–471 (2010).

  86. 86.

    et al. Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology 229, 165–170 (2003).

  87. 87.

    , , & Risks and side effects of islet transplantation. Curr. Diabetes Rep. 4, 304–309 (2004).

  88. 88.

    et al. Changes in liver enzymes after clinical islet transplantation. Transplantation 76, 1280–1284 (2003).

  89. 89.

    et al. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 53, 1311–1317 (2004).

  90. 90.

    et al. Minimal focal steatosis of liver after islet transplantation in humans: a long-term study. Cell Transplant. 14, 727–733 (2005).

  91. 91.

    et al. Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes 52, 1591–1594 (2003).

  92. 92.

    et al. Role of imaging in clinical islet transplantation. Radiographics 30, 353–366 (2010).

  93. 93.

    et al. Histologic graft assessment after clinical islet transplantation. Transplantation 88, 1286–1293 (2009).

  94. 94.

    et al. Microbial contamination of clinical islet transplant preparations is associated with very low risk of infection. Diabetes Technol. Ther. 15, 323–327 (2013).

  95. 95.

    et al. HLA sensitization in islet transplantation. Clin. Transpl. 2006, 413–420 (2006).

  96. 96.

    et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am. J. Transplant. 8, 2463–2470 (2008).

  97. 97.

    Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl. Int. 13, 313–326 (2000).

  98. 98.

    , & & Tacrolimus (FK506)-associated renal pathology. Adv. Anat. Pathol. 4, 265–276 (1997).

  99. 99.

    Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions. Expert Opin. Drug Metab. Toxicol. 10, 1585–1605 (2014).

  100. 100.

    Chemical immunosuppression in islet transplantation — friend or foe? N. Engl. J. Med. 358, 1192–1193 (2008).

  101. 101.

    , & Edmonton's islet success has indeed been replicated elsewhere. Lancet 362, 1242 (2003).

  102. 102.

    & Rapamycin in islet transplantation: friend or foe? Transpl. Int. 22, 153–161 (2009).

  103. 103.

    , , & Islet transplantation at the University of Alberta: status update and review of progress over the last decade. Can. J. Diabetes. 36, 32–37 (2012).

  104. 104.

    Achieving and maintaining insulin independence in human islet transplant recipients. Transplantation 79, 1296–1297 (2005).

  105. 105.

    , , & Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am. J. Transplant. 12, 322–329 (2012).

  106. 106.

    et al. Improving efficacy of clinical islet transplantation with iodixanol based islet purification, thymoglobulin induction and blockage of IL-1β and TNF-α. Cell Transplant. 20, 1641–1647 (2011).

  107. 107.

    et al. β-Score: an assessment of β-cell function after islet transplantation. Diabetes Care 28, 343–347 (2005).

  108. 108.

    et al. Five-year follow-up after clinical islet transplantation. Diabetes 54, 2060–2069 (2005).

  109. 109.

    , , , & Portomesenteric venous thrombosis: a community hospital experience with 103 consecutive patients. Am. J. Surg. 202, 759–763 (2011).

  110. 110.

    et al. Continuous glucose monitoring in patients with type 1 diabetes using insulin injections. Diabetes Care 39, e81–e82 (2016).

  111. 111.

    Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 59, 1285–1291 (2010).

  112. 112.

    & Pancreatic islet transplantation: is the glass half-empty or half-full? Transplantation 79, 1287–1288 (2005).

  113. 113.

    , , & The islet transplant experiment: time for a reassessment. Am. J. Transplant. 7, 2217–2218 (2007).

  114. 114.

    , & Decision time for pancreatic islet-cell transplantation. Lancet 371, 883–884 (2008).

  115. 115.

    Islet transplantation — the imperative need for continued clinical trials. Nat. Clin. Pract. Nephrol. 4, 662–663 (2008).

  116. 116.

    , , , & Pancreatic islet transplantation, what has been achieved since Edmonton break-through. Ann. Transplant. 11, 5–13 (2006).

  117. 117.

    , & Total pancreatectomy with islet autologous transplantation: the cure for chronic pancreatitis? Clin. Transl. Gastroenterol. 6, e73 (2015).

  118. 118.

    et al. Factors predicting outcomes after a total pancreatectomy and islet autotransplantation lessons learned from over 500 cases. Ann. Surg. 262, 610–622 (2015).

  119. 119.

    et al. Soluble donor DNA and islet injury after transplantation. Transplantation 92, 607–611 (2011).

  120. 120.

    , , & Immune monitoring of pancreatic islet graft: towards a better understanding, detection and treatment of harmful events. Expert Opin. Biol. Ther. 11, 55–66 (2011).

  121. 121.

    et al. Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. Transplantation 89, 361–365 (2010).

  122. 122.

    , , & The clinical impact of islet transplantation. Am. J. Transplant. 8, 1990–1997 (2008).

  123. 123.

    et al. Pathology of an islet transplant 2 years after transplantation: evidence for a nonimmunological loss. Transplantation 86, 54–62 (2008).

  124. 124.

    , , & Islet amyloid polypeptide triggers limited complement activation and binds complement inhibitor C4b-binding protein, which enhances fibril formation. J. Biol. Chem. 287, 10824–10833 (2012).

  125. 125.

    et al. Further evidence for amyloid deposition in clinical pancreatic islet grafts. Transplantation 93, 219–223 (2012).

  126. 126.

    & Glycerolipid/free fatty acid cycle and islet β-cell function in health, obesity and diabetes. Mol. Cell. Endocrinol. 353, 88–100 (2012).

  127. 127.

    et al. Advancing islet transplantation: from engraftment to the immune response. Diabetologia 54, 2494–2505 (2011).

  128. 128.

    , & Pancreas transplantation in the United States: a review. Curr. Opin. Organ Transplant. 15, 93–101 (2010).

  129. 129.

    2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev. Diabet. Stud. 8, 6–16 (2011).

  130. 130.

    , , & Impact of pancreas transplantation on type 1 diabetes-related complications. Curr. Opin. Organ Transplant. 15, 119–123 (2010).

  131. 131.

    et al. The effect of whole organ pancreas transplantation and PIT on diabetic complications. Curr. Diab. Rep. 6, 323–327 (2006).

  132. 132.

    Pancreas transplantation and diabetic complications. N. Engl. J. Med. 339, 115–117 (1998).

  133. 133.

    et al. Simultaneous pancreas–kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease. Kidney Int. 57, 2129–2135 (2000).

  134. 134.

    et al. Effect of simultaneous pancreas–kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet 353, 1915–1919 (1999).

  135. 135.

    et al. Improved survival in patients with insulin-dependent diabetes mellitus and end-stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation. Transplantation 67, 645–648 (1999).

  136. 136.

    et al. Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients. Diabetologia 49, 2977–2982 (2006).

  137. 137.

    et al. Beneficial effect of pancreas and kidney transplantation on advanced diabetic retinopathy. Cell Transplant. 9, 903–908 (2000).

  138. 138.

    & Reversal of diabetic nephropathy: lessons from pancreas transplantation. J. Nephrol. 25, 13–18 (2012).

  139. 139.

    , , , & Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type I diabetes and autonomic neuropathy. Diabetes 46, 249–257 (1997).

  140. 140.

    et al. Carotid intima media thickness decreases after pancreas transplantation. Transplantation 73, 936–940 (2002).

  141. 141.

    et al. The impact of simultaneous pancreas–kidney transplantation on long-term patient survival. Transplantation 71, 82–90 (2001).

  142. 142.

    et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J. Am. Soc. Nephrol. 14, 2150–2158 (2003).

  143. 143.

    et al. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis. Diabetes Care 30, 3063–3069 (2007).

  144. 144.

    et al. Early increase of retinal arterial and venous blood flow velocities at color Doppler imaging in brittle type 1 diabetes after islet transplant alone. Transplantation 81, 1274–1277 (2006).

  145. 145.

    et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care 28, 1358–1365 (2005).

  146. 146.

    et al. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney–pancreas and kidney-alone transplantation. Transplantation 75, 1296–1301 (2003).

  147. 147.

    et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care 26, 1129–1136 (2003).

  148. 148.

    et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation 91, 373–378 (2011).

  149. 149.

    et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 86, 1762–1766 (2008).

  150. 150.

    Beiträge zur Mikroskopischen Anatomie der Bauchspeicheldrüse (in German) (1869).

  151. 151.

    Weitere mittheilungen über den Diabetes mellitus nach exstirpation des pankreas. Berl. Klin. Wochenschr. 29, 90–94 (1892).

  152. 152.

    Notes on diabetes treated with extract and by grafts of sheep's pancreas. BMJ 2, 1303–1304 (1894).

  153. 153.

    Innesti di tessuti viventi adulti ed embrionali in alcuni organi del corpo. Policlinico III-C, 253–271 (in Italian) (1896).

  154. 154.

    Sur la transplantation du pancreas. Arch. Ital. Biol. 36, 447 (in French) (1901).

  155. 155.

    Zur normalen und pathologischen morphologie der inneren sekretion der bauchspeicheldrüse. Virchows Archiv. 168, 91 (in German) (1902).

  156. 156.

    Transplantation of pancreas in diabetes. BMJ 1, 764 (1903).

  157. 157.

    Notes on suprarenal and pancreatic grafting Lancet Neurol. 204, 550–551 (1924).

  158. 158.

    A method for the microdissection of intact pancreatic islets of mammals. Acta Endocrinol. 45, 122–132 (1964).

  159. 159.

    Isolation and culture of the islets of Langerhans of the Guinea pig. Gen. Comp. Endocrinol. 44, 342–353 (1965).

  160. 160.

    & Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16, 35–39 (1967).

  161. 161.

    , & Immunoassayable insulin content of subcellular fractions of rat islets. Endocrinology 85, 218–223 (1969).

  162. 162.

    & Transplantation of intact pancreatic islets in rats. Surgery 72, 175–186 (1972).

  163. 163.

    , & Physiological and immunological consequences of transplanting isolated pancreatic islets. Surgery 74, 91–99 (1973).

  164. 164.

    , , , & Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia 9, 486–491 (1973).

  165. 165.

    et al. Human islet transplantation: a preliminary report. Transplant. Proc. 9, 233–236 (1977).

  166. 166.

    , & A long-term functioning human pancreatic islet allotransplant. Transplantation 29, 76–77 (1980).

  167. 167.

    & Preparation of viable islet cells from dogs by a new method. Diabetes 30, 455–458 (1981).

  168. 168.

    et al. A method for large-scale, high-yield isolation of canine pancreatic islets of Langerhans. Metabolism 31, 184–187 (1982).

  169. 169.

    , , & Transplantation of cryopreserved and fresh rat islets and canine pancreatic fragments: comparison of cryopreservation protocols. Cryobiology 20, 169–184 (1983).

  170. 170.

    , & Normoglycemia after reflux of islet-containing pancreatic fragments into the splenic vascular bed in dogs. Diabetes 32, 452–459 (1983).

  171. 171.

    , , & A method for isolation of islets of Langerhans from the human pancreas. Diabetes 33, 1055–1061 (1984).

  172. 172.

    , , & Chronic pancreatitis: long-term surgical results of pancreatic duct drainage, pancreatic resection, and near-total pancreatectomy and islet autotransplantation. Surgery 96, 608–616 (1984).

  173. 173.

    et al. Islet cell transplantation in type I diabetes mellitus. Transplant. Proc. 19, 2359–2361 (1987).

  174. 174.

    , , , & Automated method for isolation of human pancreatic islets. Diabetes 37, 413–420 (1988).

  175. 175.

    , & Normoglycemia after implantation of purified islet cells in dogs. Can. J. Surg. 31, 421–426 (1988).

  176. 176.

    et al. Human islet transplantation in patients with type I diabetes. Transplant. Proc. 21, 2744–2745 (1989).

  177. 177.

    et al. Continued function of pancreatic islets after transplantation in type I diabetes. Lancet 2, 570–572 (1989).

  178. 178.

    et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 336, 402–405 (1990).

  179. 179.

    et al. Normoglycaemia after transplantation of freshly isolated and cryopreserved pancreatic islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 34, 55–58 (1991).

  180. 180.

    et al. Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients. Report of six cases. Acta Diabetol. 28, 151–157 (1991).

  181. 181.

    et al. Transplantation of porcine fetal pancreas to diabetic patients. Lancet 344, 1402–1404 (1994).

  182. 182.

    et al. New protocol toward prevention of early human islet allograft failure. Transplant. Proc. 26, 570–571 (1994).

  183. 183.

    et al. Long-term function of islet allograft in type I diabetes mellitus. Transplant. Proc. 27, 3158 (1995).

  184. 184.

    et al. Human islet isolation using a new enzyme blend. Transplant. Proc. 29, 1957–1958 (1997).

  185. 185.

    et al. Islet transplantation in IDDM patients. Diabetologia 40, 225–231 (1997).

  186. 186.

    , , & International Islet Transplant Registry Newsletter 9, (Giessen, 2001).

Download references

Acknowledgements

A.M.J.S. and C.R. are both supported through the NIH Clinical Islet Transplant (CIT) Consortium jointly funded through the National Institutes of Allergy, Immunology and Infectious Disease (NIAID) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). A.M.J.S. holds a Canada Research Chair in Regenerative Medicine and Transplantation Surgery from the Canada Research Council, and is a Senior Clinical Scholar through Alberta Innovates Healthcare Solutions (AIHS). C.R. holds the Stacy Joy Goodman Chair in Diabetes Research and is supported in part by the Diabetes Research Institute Foundation (DRIF). Both A.M.J.S. and C.R. receive grant support through the Juvenile Diabetes Research Foundation (JDRF). The clinical islet transplant program at the University of Alberta receives support from Alberta Health Services, the Government of Alberta and through the Diabetes Research Institute Foundation of Canada (DRIFCan). The Diabetes Research Institute (DRI) at the University of Miami receives support from the DRIF, the JDRF and the Leona M. and Harry B. Helmsley Charitable Trust. Both centres in Edmonton and Miami are part of the Diabetes Research Institute Federation. A.M.J.S., M.P. and C.R. are members of The Cure Alliance. M.P. is supported through the National Science Center, Poland, National Center of Science and Development, Poland, and Minister of Science and High Education, Poland.

Author information

Affiliations

  1. Clinical Islet Transplant Program, University of Alberta, 2000 College Plaza, 8215 112th Street, Edmonton, Alberta T6G 2C8, Canada.

    • A. M. James Shapiro
  2. The Diabetes Research Institute Federation, 1450 NW 10 Avenue, Miami, Florida 33136, USA.

    • A. M. James Shapiro
    • , Marta Pokrywczynska
    •  & Camillo Ricordi
  3. The Cure Alliance, 550 Bay Point Road, Miami, Florida 33137, USA.

    • A. M. James Shapiro
    • , Marta Pokrywczynska
    •  & Camillo Ricordi
  4. Department of Regenerative Medicine, Nicolaus Copernicus University in Torun, Ludwik Rydygier Medical College in Bydgoszcz, Karlowicza 24 Street, 85–092 Bydgoszcz, Poland.

    • Marta Pokrywczynska
  5. Diabetes Research Institute and Cell Transplant Program, University of Miami Miller School of Medicine, 1450 NW 10th Avenue, Miami, Florida 33136, USA.

    • Camillo Ricordi

Authors

  1. Search for A. M. James Shapiro in:

  2. Search for Marta Pokrywczynska in:

  3. Search for Camillo Ricordi in:

Contributions

All author contributed to all aspects of the manuscript.

Competing interests

C.R. is co-inventor on patents related to pancreatic islet processing that are in part used for current islet cell product manufacturing. However, he is not receiving any royalty or financial benefit from these patents, or from islet cell processing activities. The other authors declare no competing interests.

Corresponding authors

Correspondence to A. M. James Shapiro or Camillo Ricordi.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrendo.2016.178

Further reading